CN102973884A - Traditional Chinese medicine preparation for treatment of gallstones and cholecystitis and preparation method thereof - Google Patents

Traditional Chinese medicine preparation for treatment of gallstones and cholecystitis and preparation method thereof Download PDF

Info

Publication number
CN102973884A
CN102973884A CN2012104385589A CN201210438558A CN102973884A CN 102973884 A CN102973884 A CN 102973884A CN 2012104385589 A CN2012104385589 A CN 2012104385589A CN 201210438558 A CN201210438558 A CN 201210438558A CN 102973884 A CN102973884 A CN 102973884A
Authority
CN
China
Prior art keywords
parts
radix
filtrate
rhizoma
employ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012104385589A
Other languages
Chinese (zh)
Inventor
赵步长
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHAANXI BUCHANG HIGH-TECH PHARMACEUTICAL Co Ltd
Original Assignee
SHAANXI BUCHANG HIGH-TECH PHARMACEUTICAL Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHAANXI BUCHANG HIGH-TECH PHARMACEUTICAL Co Ltd filed Critical SHAANXI BUCHANG HIGH-TECH PHARMACEUTICAL Co Ltd
Priority to CN2012104385589A priority Critical patent/CN102973884A/en
Publication of CN102973884A publication Critical patent/CN102973884A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a traditional Chinese medicine preparation for treatment of gallstones and cholecystitis and a preparation method thereof. The raw materials of the traditional Chinese medicine preparation include 165 parts of radix bupleuri, 165 parts of pericarpium citri reticulatae viride, 165 parts of scutellaria baicalensis, 165 parts of white peony root, 66 parts of rhubarb, 165 parts of radix curcumae, 165 parts of lysimachia christinae hance, 165 parts of lygodium japonicum, 165 parts of endothelium corneum gigeriae galli, 165 parts of oriental wormwood, 165 parts of rhizoma curcumae longae, 110 parts of rhizoma sparganii, and 165 parts of radix clematidis. The traditional Chinese medicine preparation is prepared by extracting and purifying according to a certain process, and added with a pharmacy-acceptable accessory. The traditional Chinese medicine preparation of the invention has the characteristics of simple preparation process, safety and effectiveness, and significant pharmacological effects.

Description

A kind of Chinese medicine preparation for the treatment of cholelithiasis, cholecystitis and preparation method thereof
Technical field
The present invention relates to a kind of Chinese medicine preparation for the treatment of cholelithiasis, cholecystitis and preparation method thereof, belong to the pharmaceutical preparations technology field.
Background technology
Raising along with the social life level, the quickening of rhythm of life, the incidence rate of cholecystitis, gallstone disease is in rising trend, and the multiple 35-55 middle age in year of being born in, and belongs to the category of the diseases such as Chinese medicine " hypochondriac pain ", " abdominal distention ", " gallbladder-distention ", " jaundice ".What Chinese medicine was thought its morbidity is because feelings will is uncomfortable, eating and drinking without temperance, and damp and hot interior life is due to cannot not penting up loosely.Disease is defended mainly in liver and gall, relates to spleen, stomach, large intestine, and main pathogenesis is that liver and gall are lost and dredged, retention of damp-heat in the interior, and incoordination between the liver and stomach, bile excretion is not smooth, and calculus is blocked, and the gallbladder internal organs is obstructed, and its pathological product forms cholelithiasis.The passages through which vital energy circulates of liver and gall is distributed in that the side of body is lower, and QI stagnation of the liver and galibladder, vim and vigour are not smooth, stagnation of QI and blood may bring about pain, so see the right flank distending pain, the time heavy when light, in time, end when sending out; Damp-heat accumulation is loose, generates calculus, so persistence distending pain or angor under your upper right abdomen or the xiphoid-process; Sick at gallbladder, contrary at stomach, QI depression of the liver and gallbladder, perverse and unreasonable manner is violated stomach, and the disease of seeing the adverse rising of stomach-QI such as nausea and vomiting; If bile is not smooth, jaundice then appears in excessive skin, bitter taste, oliguria with reddish urine, red tongue with yellowish and greasy fur, stringy and rolling pulse and number average belongs to resembling of dampness-heat in the liver and gallbladder.Control suitable depressed liver-energy dispersing and function of gallbladder promoting calculus, Qinghua is damp and hot, the method for promoting the circulation of QI to relieve pain.
The invention provides a kind of Chinese medicine preparation for the treatment of cholelithiasis, cholecystitis, its prescription is comprised of 13 flavor Chinese medicines, for QI stagnation of the liver and galibladder, the cards such as damp-heat blocking in the body, calculus block, and the gallbladder internal organs is obstructed have the very clinical treatment effect of produce effects, between this, we have successively applied for following 2 patents of invention for this Chinese medicine composition, and its publication number is respectively CN1418682A, CN1562178A, and open day is respectively 2002.11.29 and 2004.03.17; Above patent of invention file discloses, protects from aspects such as different amounts of components, different preparation technology and dosage forms; and the application's patent is to carry out on this basis a large amount of experimentatioies; with further replenishment of process preparation method; improving preparation stability and bioavailability is purpose, and creationary a kind of Chinese medicine preparation for the treatment of cholelithiasis, cholecystitis of succeeding in developing.
Summary of the invention
The object of the invention is to provide a kind of steady quality, and curative effect is reliable, the treatment cholelithiasis that bioavailability is high, the Chinese medicine preparation of cholecystitis.
Another object of the present invention is to provide the preparation method of the Chinese medicine preparation of this treatment cholelithiasis, cholecystitis, the method is simple and feasible, meet absorption process in the oral medicine object, the Chinese medicine preparation good stability that finally makes, and curative effect is reliably remarkable.
Technical solution of the present invention is realized by following step:
A. prescription forms: 165 parts of Radix Bupleuri, 165 parts on Pericarpium Citri Reticulatae Viride, 165 parts of Radix Scutellariaes, 165 parts of the Radix Paeoniae Albas, 66 parts of Radix Et Rhizoma Rhei, 165 parts of Radix Curcumaes, 165 parts of Herba Lysimachiaes, 165 parts of Spora Lygodii, 165 parts of Endothelium Corneum Gigeriae Galli, 165 parts of Herba Artemisiae Scopariaes, 165 parts in Rhizoma Curcumae Longae, 110 parts of rhizoma sparganic, 165 parts of Radix Clematidis;
B. preparation method: with above-mentioned 13 flavor Chinese crude drugs, in the steps below operations:
⑴ get Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Radix Scutellariae, Radix Curcumae, Rhizoma Curcumae Longae, Herba Artemisiae Scopariae, rhizoma sparganic medical material, and adding with the medical material weight ratio is that 6~12 times of amounts, concentration are 50%~80% ethanol, heating extraction 1~3 time, and each 1~2 hour, filter, filtrate, medicinal residues are continued to employ;
⑵ mix the medicinal residues among the above-mentioned ⑴ with the Radix Paeoniae Alba, Radix Et Rhizoma Rhei, Herba Lysimachiae, Spora Lygodii, Endothelium Corneum Gigeriae Galli, clematis chinensis medicinal materials, adding with the medical material weight ratio is that 5~10 times of amounts, pH value are 3.0~5.5 water, heating extraction 1~3 time, each 1~2 hour, filter, add ethanol in the filtrate so that contain the alcohol amount and reach 50%~80%, leave standstill, filter, filtrate is continued to employ;
⑶ mix the filtrate of continuing to employ at two places among above-mentioned ⑴ and the ⑵, and Recycled ethanol adds water to without behind the alcohol flavor, leaves standstill, and after the filtration, adds antiseptic and correctives commonly used, adds water to full dose and make oral liquid.
Technical solution of the present invention is specifically realized by following steps:
A. prescription forms: 165 parts of Radix Bupleuri, 165 parts on Pericarpium Citri Reticulatae Viride, 165 parts of Radix Scutellariaes, 165 parts of the Radix Paeoniae Albas, 66 parts of Radix Et Rhizoma Rhei, 165 parts of Radix Curcumaes, 165 parts of Herba Lysimachiaes, 165 parts of Spora Lygodii, 165 parts of Endothelium Corneum Gigeriae Galli, 165 parts of Herba Artemisiae Scopariaes, 165 parts in Rhizoma Curcumae Longae, 110 parts of rhizoma sparganic, 165 parts of Radix Clematidis;
B. preparation method: with above-mentioned 13 flavor Chinese crude drugs, in the steps below operations:
⑴ get Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Radix Scutellariae, Radix Curcumae, Rhizoma Curcumae Longae, Herba Artemisiae Scopariae, rhizoma sparganic medical material, and adding with the medical material weight ratio is that 10 times of amounts, concentration are 70% ethanol, heating extraction 2 times, and each 1.5 hours, filter, filtrate, medicinal residues are continued to employ;
⑵ mix the medicinal residues among the above-mentioned ⑴ with the Radix Paeoniae Alba, Radix Et Rhizoma Rhei, Herba Lysimachiae, Spora Lygodii, Endothelium Corneum Gigeriae Galli, clematis chinensis medicinal materials, adding with the medical material weight ratio is that 8 times of amounts, pH value are 4.0 water, heating extraction 2 times, each 1.5 hours, filter, add ethanol in the filtrate so that contain the alcohol amount and reach 70%, leave standstill, filter, filtrate is continued to employ;
⑶ mix the filtrate of continuing to employ at two places among above-mentioned ⑴ and the ⑵, and Recycled ethanol adds water to without behind the alcohol flavor, leaves standstill, and after the filtration, adds antiseptic and correctives commonly used, adds water to full dose and make oral liquid.
Chinese medicine preparation of the present invention cures mainly the cards such as cholelithiasis, cholecystitis and belongs to QI stagnation of the liver and galibladder, damp-heat blocking in the body person.Radix Bupleuri dispersing the stagnated live-QI to relieve the stagnation of QI in the prescription, the disease of kind treating the liver gallbladder; The Herba Lysimachiae eliminating damp-heat, cholagogic and lithagogue is treating the liver cholelithiasis key medicine.Two medicines match, and the depressed liver-energy dispersing and function of gallbladder promoting calculus is monarch drug altogether.Radix Scutellariae clearing gallbladder heat and dampness; The Radix Et Rhizoma Rhei heat clearing and blood circulation promoting pushes away Chen Zhixin, helps altogether Herba Lysimachiae to clear away the dampness and heat, and cholagogic and lithagogue is with being ministerial drug.The Spora Lygodii clearing away heat and promoting diuresis, it is damp and hot to disappear; The treating stranguria fossil of Endothelium Corneum Gigeriae Galli, the kind cholelithiasis of controlling; The Herba Artemisiae Scopariae clearing away heat-damp and promoting diuresis is logical yellow; Rhizoma Curcumae Longae, rhizoma sparganic, Radix Clematidis promoting flow of QI and blood, removing obstruction in the collateral to relieve pain; Radix Paeoniae Alba relieving spasm to stop pain, above-mentioned seven flavor medicine material is assisted the monarch and his subjects' promoting the circulation of QI to relieve pain altogether, and Qinghua is damp and hot, and cholagogic and lithagogue is adjuvant drug altogether.Radix Bupleuri draws all medicines and enters liver and gall, the double usefulness that makes medicine of doing.All medicines match, and are total to long memorial liver cholagogic and lithagogue, and Qinghua is damp and hot, the merit of promoting flow of QI and blood pain relieving.
We are in the middle of the research process of reality, and than 2 patents of invention in first to file, its main creation point is the extraction purification aspect of medical material, has brought thus significant technological progress, and its main beneficial effect is as follows.
Chinese medicine preparation of the present invention is by Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Radix Scutellariae, the Radix Paeoniae Alba, the pure Chinese medicine of 13 flavors such as Radix Et Rhizoma Rhei forms, Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Radix Scutellariae, Radix Curcumae, Rhizoma Curcumae Longae, Herba Artemisiae Scopariae, in the rhizoma sparganic 7 flavor medical materials, contain a large amount of pure dissolubilities and water solublity active component, therefore, we carry out first the ethanol extraction liposoluble constituent to it, again with medicinal residues and the Radix Paeoniae Alba, Radix Et Rhizoma Rhei, Herba Lysimachiae, Endothelium Corneum Gigeriae Galli, Spora Lygodii and Radix Clematidis contain peoniflorin, the medical material of the water-soluble components such as emodin mixes, adopt acid extraction, the refining method of precipitate with ethanol is processed, so both extracted comprehensively and kept effective ingredient, can make with extra care again, simplify the operation course, thus energy savings, dwindle production cost.Therefore in conjunction with the extracting method of above-mentioned medical material, we finally are made into oral liquid evident in efficacy by the creative work of hardships.In a word, the technical scheme of extraction purification of the present invention, molding is that we are in the research process of reality, by unremitting groping and accidental discovery, and the clinical practice demand of the said preparation of comprehensively having investigated, reasonably plan as a whole, comparison and the process route that draws, thereby guaranteed science, the high efficiency of the Chinese medicine preparation finally made.
It below is the pharmacodynamic study test to technical solution of the present invention, because core innovative point of the present invention is the extraction and purification process aspect of medical material, and with we previous disclosed publication number CN1418682A, after the patent document contrast of CN1562178A, we are take the technical scheme of publication number CN1418682A as correlation technique, therefore we in pharmacodynamic experiment take the two technology contents as contrast, research level in conjunction with modern pharmacology, and pass through in the body, outer lithodialysis test, impact on the rat bile secretion, the antagonism cholelithiasis of medicine of the present invention has been illustrated in the tests such as anti-inflammatory and antalgic fully, the pharmacodynamics curative effect of cholecystitis.In order to simplify experimental implementation, save research expenditure, follow the experiment principle of parallel control, get rid of the Different therapeutical effect that each medicine group is brought because of dosage form itself, thereby the creativeness of the outstanding technical solution of the present invention of science more, we study take the middle product group of one of them disclosed technical scheme as representative, right this can be derived for those skilled in the art fully thus, understand the beneficial effect of other parameter point technical scheme among the application, so the technology of the present invention content and drug effect result never are limited to this scope.
1 test material and result processing method:
1.1 the preparation of trial drug:
The preparation of A trial drug of the present invention:
⑴ get Radix Bupleuri 165g, Pericarpium Citri Reticulatae Viride 165g, Radix Scutellariae 165g, Radix Curcumae 165g, Rhizoma Curcumae Longae 165g, Herba Artemisiae Scopariae 165g, rhizoma sparganic 110g medical material, adding with the medical material weight ratio is that 10 times of amounts, concentration are 70% ethanol, heating extraction 2 times, each 1.5 hours, filter, filtrate, medicinal residues are continued to employ;
⑵ mix the medicinal residues among the above-mentioned ⑴ with Radix Paeoniae Alba 165g, Radix Et Rhizoma Rhei 66g, Herba Lysimachiae 165g, Spora Lygodii 165g, Endothelium Corneum Gigeriae Galli 165g, Radix Clematidis 165g medical material, adding with the medical material weight ratio is that 8 times of amounts, pH value are 4.0 water, heating extraction 2 times, each 1.5 hours, filter, add ethanol in the filtrate so that contain the alcohol amount and reach 70%, leave standstill, filter, filtrate is continued to employ;
⑶ mix the filtrate of continuing to employ at two places among above-mentioned ⑴ and the ⑵, and Recycled ethanol concentrates, is dried and crushed into dried cream powder to without behind the alcohol flavor, continues to employ; Before use, adding distil water is mixed with medicinal liquid, namely gets the middle product group of medicine of the present invention.
The preparation of product group in the middle of the B.CN1418682A contrast:
⑴ it is for subsequent use that be ground into fine powder with Radix Et Rhizoma Rhei 66g;
⑵ extract volatile oil with Herba Artemisiae Scopariae 165g, Radix Curcumae 165g, Pericarpium Citri Reticulatae Viride 165g, Rhizoma Curcumae Longae 165g, rhizoma sparganic 110g, for subsequent use; Aqueous solution after the distillation filters, and filtrate in addition device is collected; Medicinal residues decoct with water 2 times with Radix Bupleuri 165g, Radix Scutellariae 165g, Radix Paeoniae Alba 165g, Herba Lysimachiae 165g, Spora Lygodii 165g, Endothelium Corneum Gigeriae Galli 165g, Radix Clematidis 165g again, and each 1.5h filters, filtrate after filtrate and the distillation merges, and is condensed into clear paste, adds ethanol and makes and contain the alcohol amount and reach 50%, stir evenly, cold preservation 24 hours filters, decompression filtrate recycling ethanol continues to be condensed into thick paste, vacuum drying, get dry extract, be ground into fine powder, with Radix Et Rhizoma Rhei fine powder and volatile oil mixing, namely get total mixture; Before use, adding distil water is mixed with the medicinal liquid identical with product group concentration in the middle of the invention described above, namely gets the middle product group of CN1418682A contrast.
1.2 experimental animal: Kunming mouse, SD rat and rabbit are provided by The Fourth Military Medical University's Experimental Animal Center.
1.3 test method: observe the test of the inside and outside dissolving cholelithiasis of each medicine group body, on tests such as the impact of rat bile secretion and anti-inflammatory and analgesic effects.
1.4 statistical procedures: experimental result with
Figure BDA0000236410371
Expression adopts the t check to measure the significance of group difference.
2 test methods and result:
2.1 external lithodialysis test
With the dry pigment complex stone of shape, size, similar weight, be divided at random 3 groups, 10 every group.Every group of cholelithiasis placed the ground test tube with ground stopper that fills 6ml tested material solution, and every pipe l grain places test tube 37 ℃ of constant temperature water baths again, and every 24h observes 1 time, and every 24h changes liquid 1 time, Continuous Observation 15 days.Take out cholelithiasis on the 16th day, weigh after to be dried, calculate the difference of the forward and backward cholelithiasis weight of lithodialysis, the results are shown in Table 1.
The external litholytic effect research of table 1 (n=10,
Figure BDA0000236410372
)
Figure BDA0000236410373
Annotate: compare with the normal saline group, * *P<0.001; Compare with CN1418682A medicine group, P<0.05.
By the experimental data of table 1 as can be known: in the middle of the medicine of the present invention in the middle of product group and the CN1418682A contrast product group and normal saline group relatively, both all can reduce the weight of cholelithiasis significantly in external lithodialysis test, and have reached extremely significantly statistical significance; Compare with product group in the middle of the CN1418682A contrast, the product group is larger to the weight differential of external cholelithiasis before and after effect in the middle of the present invention, also has outstanding diversity effect, the result of study prompting: product can reduce the volume and weight of external cholelithiasis significantly in the middle of of the present invention, and it is had obvious therapeutical effect.
2.2 lithodialysis experimental study in the body
Get 30 of rabbit, with containing 6 weeks of 1% dihydrocholesterol forage feed.Be divided at random 3 groups in the 3rd week: be respectively normal saline matched group, the middle product group of the present invention and the middle product group of CN1418682A.Each test group is with gastric infusion, and successive administration under narcotism, is cut the rabbit abdominal cavity open after 3 weeks, and the ligation bile duct takes out and the incision gallbladder, allows bile flow in the filter cloth, has flowed rear visible a plurality of cholelithiasis until liquid.Filter cloth is put dry 12h in 60 ℃ of baking ovens, take out filter cloth, accurately weigh and deduct former filter cloth dry weight, be the gross weight of cholelithiasis, experimental result sees Table 2.
The research of litholytic effect in table 2 body (
Figure BDA0000236410374
)
Figure BDA0000236410375
Annotate: compare with the normal saline group, * *P<0.001; Compare with CN1418682A medicine group, P<0.05.
By the experimental data of table 2 as can be known: product group and normal saline group be relatively in the middle of product group, the CN1418682A contrast in the middle of the medicine of the present invention, both all can obviously reduce the weight of cholelithiasis in the rabbit body, and compare with the cholelithiasis weight of normal saline group and to have reached significant diversity; Compare with product group in the middle of the CN1418682A contrast, the product group makes the weight reducing of proper inner bag stone in the middle of the present invention, has also reached statistical meaning.
2.3 the impact on the rat bile secretory volume
Get 30 of SD rats, water is can't help in the 12h fasting before the experiment, after weighing during experiment, is divided at random 3 groups: be respectively normal saline matched group, the middle product group of the present invention and the middle product group of CN1418682A.Then every Mus with pentobarbital sodium 40mg/kg intraperitoneal injection of anesthesia after, open the abdominal cavity, find bile duct, do " V " shape to the liver direction and cut bile duct, insert plastic tube and fixing, visible pistac bile flows out subsequently.After stablizing 20min, collect first 30min bile, then respectively organize rat is given respectively above grouping by duodenum saline or medicinal liquid.Collect a bile every 30min after the administration, totally 3 times, the record choleresis the results are shown in Table 3.
Table 3 on the impact of rat bile secretory volume (n=10, )
Figure BDA0000236410377
Annotate: compare with the normal saline group, *P<0.05, *P<0.01, * *P<0.001; Compare with CN1418682A medicine group, P<0.05, △ △P<0.01.
As shown in Table 3: compare with the normal saline group, in the middle of the medicine of the present invention in the middle of product group, the CN1418682A contrast product group for administration after 30min, 60min, 90min rat bile secretory volume has and significantly increases effect, and in above-mentioned 3 time periods potentiation is arranged all, and reached significant diversity effect; Compare with product group in the middle of the CN1418682A contrast, product group above-mentioned 3 time points after administration in the middle of the present invention all have the effect of significant enhancing rat bile secretion, and have reached statistical significance.Results suggest: medicine group of the present invention is of value to the treatment of gallbladder class disease for the choleresis showed increased of rat, and relatively has more excellent therapeutical effect with the CN1418682A contrast groups.
2.4 antiinflammatory experimental study
2.4.1 xylol causes the impact of chmice acute inflammation:
Get 30 of mices, be divided at random 3 groups, be administered once every day, gastric infusion 7d, behind last administration lh, be coated with dimethylbenzene 0.05ml in the mouse right ear positive and negative, to 2h behind the dimethylbenzene, put to death animal, cut ear, sweep away auricle in corresponding site with the 8mm steel drift, weigh, take the difference of left and right sides ear weight as the swelling degree, the results are shown in Table 4.
Table 4 xylol cause mice ear impact ( )
Annotate: compare with the normal saline group, * *P<0.001; Compare with CN1418682A medicine group, △ △P<0.01.
2.4.2 the impact on the mice granuloma induced by implantation of cotton pellets: get 30 mices, be divided at random 3 groups, every group 10, implant each 1 of 5mg sterilized cotton ball, gastric infusion respectively at oxter, the mice left and right sides, every day 1 time, 7d puts to death animal behind last administration lh altogether, gets granuloma induced by implantation of cotton pellets, weigh (weight in wet base), the results are shown in Table 5.
Table 5 on the granulomatous impact of mice cotton balls number (
Figure BDA00002364103710
, mg)
Figure BDA00002364103711
Annotate: compare with the normal saline group, *P<0.05, *P<0.01; Compare with CN1418682A medicine group, P<0.05.
Result of the test by table 4 and 5 shows: compare with the normal saline matched group, product group, the middle product group of CN1418682A contrast all have good antiinflammatory action, and have reached significant diversity effect in the middle of the medicine of the present invention in above-mentioned antiinflammatory experiment; In the middle of the medicine of the present invention in the middle of product group and the CN1418682A contrast product group relatively count the antiinflammatory such as granuloma at acute inflammation, mice cotton balls and all have significant diversity in testing, obvious statistical significance is arranged; Results suggest: the product group has good therapeutical effect to the inflammatory model of mice in the middle of the medicine group of the present invention, and significantly is better than the drugs compared group.
2.5 analgesic experiment
2.5.1 mice acetic acid is caused the effect of writhing response: 30 of mices, be divided at random 3 groups, be administered once every day, gastric infusion is 5 days continuously, and behind last gastric infusion lh, lumbar injection 0.6% glacial acetic acid 0.2ml/ only, observe mouse writhing number of times in the 20min, the results are shown in Table 6.
The analgesic activity of table 6 pair mice acetic acid twisting reaction (
Figure BDA00002364103712
)
Figure BDA00002364103713
Annotate: compare with the normal saline group, *P<0.01, * *P<0.001; Compare with CN1418682A medicine group, P<0.05.
2.5.2 the impact on mice electricity irritation whipping pain threshold: 30 of mices, be divided at random 3 groups, be administered once every day, gastric infusion is 5 days continuously, behind last gastric infusion lh, an electrode is put on the mice foot, another electrode stimulating afterbody, after the energising, the pain threshold when observing the mice whipping the results are shown in Table 7.
Electricity irritation suppression ratio=(administration group pain threshold-matched group pain threshold)/matched group pain threshold * 100%.
Table 7 is on the impact of mice electricity irritation whipping pain threshold
Figure BDA00002364103714
Annotate: compare with the normal saline group, *P<0.01; Compare with CN1418682A medicine group, P<0.05.
Show that from table 6 and table 7 result the analgesic effect of product group in the middle of product group and the CN1418682A contrast more all has significant difference with the normal saline matched group in the middle of the medicine of the present invention; The middle product group of product group and CN1418682A contrast relatively can obviously reduce the writhing number of times in the middle of the medicine of the present invention in the mice acetic acid twisting, can significantly improve pain threshold in the experiment of mice electricity irritation whipping pain threshold, and the significant difference effect is all arranged.Results suggest: medicine group of the present invention has better analgesic activity effect.
In above-mentioned pharmacodynamic experiment, we are by the improvement effect of the different animal experiment evaluation index of examination, no matter the product group is external in the middle of can finding out medicine of the present invention, all has good therapeutical effect in the lithodialysis test in the body, obviously can improve the secretory volume of bile, to anti-inflammatory, strengthen analgesic activity, results suggest: pharmaceutical preparation of the present invention can have good treatment cholelithiasis, the effect of cholecystitis, and can alleviate the pain of this type of Disease, its whole curative effect has more excellent therapeutical effect than the technical scheme of previous disclosed correlation technique CN1418682A group, outstanding embodiment the useful technique effect of medicine of the present invention.
The specific embodiment
Below be the specific embodiment of content of the present invention, be used for setting forth the technical scheme that present specification is wanted the technical solution problem, help those skilled in the art to understand content of the present invention, but the realization of technical solution of the present invention is not limited to these embodiment.
Embodiment 1
⑴ get Radix Bupleuri 165g, Pericarpium Citri Reticulatae Viride 165g, Radix Scutellariae 165g, Radix Curcumae 165g, Rhizoma Curcumae Longae 165g, Herba Artemisiae Scopariae 165g, rhizoma sparganic 110g medical material, adding with the medical material weight ratio is that 10 times of amounts, concentration are 70% ethanol, heating extraction 2 times, each 1.5 hours, filter, filtrate, medicinal residues are continued to employ;
⑵ mix the medicinal residues among the above-mentioned ⑴ with Radix Paeoniae Alba 165g, Radix Et Rhizoma Rhei 66g, Herba Lysimachiae 165g, Spora Lygodii 165g, Endothelium Corneum Gigeriae Galli 165g, Radix Clematidis 165g medical material, adding with the medical material weight ratio is that 8 times of amounts, pH value are 4.0 water, heating extraction 2 times, each 1.5 hours, filter, add ethanol in the filtrate so that contain the alcohol amount and reach 70%, leave standstill, filter, filtrate is continued to employ;
⑶ mix the filtrate of continuing to employ at two places among above-mentioned ⑴ and the ⑵, and Recycled ethanol adds water to without behind the alcohol flavor, leaves standstill, and after the filtration, adds antiseptic and correctives commonly used, adds water to 1000ml and make oral liquid.
Embodiment 2
⑴ get Radix Bupleuri 165g, Pericarpium Citri Reticulatae Viride 165g, Radix Scutellariae 165g, Radix Curcumae 165g, Rhizoma Curcumae Longae 165g, Herba Artemisiae Scopariae 165g, rhizoma sparganic 110g medical material, adding with the medical material weight ratio is that 6 times of amounts, concentration are 50% ethanol, heating extraction 1 time, each 2 hours, filter, filtrate, medicinal residues are continued to employ;
⑵ mix the medicinal residues among the above-mentioned ⑴ with Radix Paeoniae Alba 165g, Radix Et Rhizoma Rhei 66g, Herba Lysimachiae 165g, Spora Lygodii 165g, Endothelium Corneum Gigeriae Galli 165g, Radix Clematidis 165g medical material, adding with the medical material weight ratio is that 10 times of amounts, pH value are 3.0 water, heating extraction 3 times, each 1 hour, filter, add ethanol in the filtrate so that contain the alcohol amount and reach 80%, leave standstill, filter, filtrate is continued to employ;
⑶ mix the filtrate of continuing to employ at two places among above-mentioned ⑴ and the ⑵, and Recycled ethanol adds water to without behind the alcohol flavor, leaves standstill, and after the filtration, adds antiseptic and correctives commonly used, adds water to 1000ml and make oral liquid.
Embodiment 3
⑴ get Radix Bupleuri 165g, Pericarpium Citri Reticulatae Viride 165g, Radix Scutellariae 165g, Radix Curcumae 165g, Rhizoma Curcumae Longae 165g, Herba Artemisiae Scopariae 165g, rhizoma sparganic 110g medical material, adding with the medical material weight ratio is that 12 times of amounts, concentration are 80% ethanol, heating extraction 3 times, each 1 hour, filter, filtrate, medicinal residues are continued to employ;
⑵ mix the medicinal residues among the above-mentioned ⑴ with Radix Paeoniae Alba 165g, Radix Et Rhizoma Rhei 66g, Herba Lysimachiae 165g, Spora Lygodii 165g, Endothelium Corneum Gigeriae Galli 165g, Radix Clematidis 165g medical material, adding with the medical material weight ratio is that 5 times of amounts, pH value are 5.5 water, heating extraction 1 time, each 2 hours, filter, add ethanol in the filtrate so that contain the alcohol amount and reach 50%, leave standstill, filter, filtrate is continued to employ;
⑶ mix the filtrate of continuing to employ at two places among above-mentioned ⑴ and the ⑵, and Recycled ethanol adds water to without behind the alcohol flavor, leaves standstill, and after the filtration, adds antiseptic and correctives commonly used, adds water to 1000ml and make oral liquid.
In order further to verify the curative effect of finished product preparation of the present invention, we have carried out corresponding clinical trial with the medicine for preparing among the above-mentioned specific embodiment 1-3, and are existing that report the test is as follows.
⑴ object of study: choose tested case 218 examples in the step-length hospital of traditional Chinese hospital in year July, in March, 2006~2008,8 examples that come off, person's 210 examples of including the statistical analysis in midway.Adopt parallel control, method for designing at random, be divided at random 4 groups, 1 group of 54 example of embodiment wherein, male's 34 examples wherein, women's 20 examples, mean age (45.1 ± 1.3) year; 2 group of 52 example of embodiment, male's 31 examples wherein, women's 21 examples, year mean age (43.8 ± 2.6); 3 group of 53 example of embodiment, male's 34 examples wherein, women's 19 examples, year mean age (43.2 ± 1.7); Matched group (XIAOYAN LIDAN PIAN group) 51 examples, male's 35 examples wherein, women's 16 examples, average (42.5 ± 2.4) year.
⑵ case is selected:
A tcm diagnosis standard main symptom: the right flank distending pain is often involved right shoulder, or epigastric fullness, stringy pulse; Inferior card: pain, vexed swollen because the variation of feelings will increases and decreases, uncomfortable in chest easypro, sighing frequently, bitter taste is felt sick, and the decreased food intake of receiving is few, and belch is done frequently, and it is uncomfortable to defecate.
B Western medicine diagnose standard: 1. continue upper right abdomen dull pain or sense of discomfort or omoplate district pain; 2. the indigestion symptoms such as nauseating, belch, pantothenic acid, abdominal distention and scorching hot are arranged, the postemphasis of feed greasy food; 3. the course of disease is longer, and the course of disease is through having acute attack and alleviating characteristics alternately; 4. gallbladder area has mild tenderness or percussion pain; 5. the visible gallbladder wall of B ultrasonic crude, thicken, gallbladder dwindles or is out of shape or with cholelithiasis; 6. the visible gallbladder of cholecystography dwindles or is out of shape, and gallbladder contraction function is bad or the gallbladder development is thin, visible cholelithiasis.All according to above-mentioned 5., 6. add 1. one of in-4. in 2 above persons can make a definite diagnosis.
⑶ method:
With prepared oral liquid among the invention described above embodiment 1-3 and in the following manner administration of matched group: the patient takes medicine 3 every day, and each 6 measurement units (6ml, 6) after 15 skies are 1 course for the treatment of, are judged efficacy result 2 courses for the treatment of.
⑷ criterion of therapeutical effect:
1. recovery from illness: symptom, sign disappear, and haemanalysis and liver function are normal, and image check shows that the wall thickness of gallbladder or bile duct wall, crude, 3 of entrant sounds recover normal, and calculus is all discharged; 2. produce effects: symptom, sign disappear, and haemanalysis and liver function are normal, and image check shows that 2 are recovered normal in the wall thickness of gallbladder or bile duct wall, crude, the entrant sound, calculus is most of discharge or the calculus decreased number greater than original 1/3; 3. effective: symptom, sign are most of to disappear, and haemanalysis is normal, and liver function takes a turn for the better, and image check shows in the wall thickness of gallbladder or bile duct wall, crude, the entrant sound and be improved more than 1, calculus is most of discharge or the calculus decreased number less than original 1/3; 4. invalid: unchanged before and after the treatment.
⑸ statistical method:
1. ranked data are with Ridit check, rank test; 2. enumeration data X 2 test; 3. measurement data is with t check, variance analysis.
⑹ results and analysis:
1 group of 20 example of fully recovering of embodiment, produce effects 17 examples, effective 10 examples, invalid 7 examples, cure-remarkable-effectiveness rate 68.5%, total effective rate 87.0%; 2 groups of 17 examples of fully recovering of embodiment, produce effects 19 examples, effective 10 examples, invalid 6 examples, cure-remarkable-effectiveness rate 69.2%, total effective rate 88.5%; 3 groups of 17 examples of fully recovering of embodiment, produce effects 20 examples, effective 9 examples, invalid 7 examples, cure-remarkable-effectiveness rate 69.8%, total effective rate 86.8%; Matched group 15 examples of fully recovering, produce effects 13 examples, effective 5 examples, invalid 18 examples, cure-remarkable-effectiveness rate 54.9%, total effective rate 64.7%.
Above clinical efficacy results suggest: the medicine of technical solution of the present invention preparation is aspect treatment cholecystitis, cholelithiasis, and each dosage form all has the curing protrusion effect, and curative effect is better than matched group.Results suggest Chinese medicine preparation of the present invention has the advantages such as preparation technology is efficiently feasible, drug effect is clear and definite, stable curative effect is reliable, its beneficial effect is no matter from the extraction and purification process of medicine, or on the forming technique of finished product preparation, all effectively guaranteed the excellent results of preparation of the present invention, this will bring for the clinical practice of this Chinese medicine preparation huge potentiality and development space.

Claims (4)

1. Chinese medicine preparation for the treatment of cholelithiasis, cholecystitis is characterized in that it is to be prepared from by following technique:
A. prescription forms: 165 parts of Radix Bupleuri, 165 parts on Pericarpium Citri Reticulatae Viride, 165 parts of Radix Scutellariaes, 165 parts of the Radix Paeoniae Albas, 66 parts of Radix Et Rhizoma Rhei, 165 parts of Radix Curcumaes, 165 parts of Herba Lysimachiaes, 165 parts of Spora Lygodii, 165 parts of Endothelium Corneum Gigeriae Galli, 165 parts of Herba Artemisiae Scopariaes, 165 parts in Rhizoma Curcumae Longae, 110 parts of rhizoma sparganic, 165 parts of Radix Clematidis;
B. preparation method: with above-mentioned 13 flavor Chinese crude drugs, in the steps below operations:
⑴ get Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Radix Scutellariae, Radix Curcumae, Rhizoma Curcumae Longae, Herba Artemisiae Scopariae, rhizoma sparganic medical material, and adding with the medical material weight ratio is that 6~12 times of amounts, concentration are 50%~80% ethanol, heating extraction 1~3 time, and each 1~2 hour, filter, filtrate, medicinal residues are continued to employ;
⑵ mix the medicinal residues among the above-mentioned ⑴ with the Radix Paeoniae Alba, Radix Et Rhizoma Rhei, Herba Lysimachiae, Spora Lygodii, Endothelium Corneum Gigeriae Galli, clematis chinensis medicinal materials, adding with the medical material weight ratio is that 5~10 times of amounts, pH value are 3.0~5.5 water, heating extraction 1~3 time, each 1~2 hour, filter, add ethanol in the filtrate so that contain the alcohol amount and reach 50%~80%, leave standstill, filter, filtrate is continued to employ;
⑶ mix the filtrate of continuing to employ at two places among above-mentioned ⑴ and the ⑵, and Recycled ethanol adds water to without behind the alcohol flavor, leaves standstill, and after the filtration, adds antiseptic and correctives commonly used, adds water to full dose and make oral liquid.
2. the Chinese medicine preparation for the treatment of cholelithiasis as claimed in claim 1, cholecystitis is characterized in that it is to be prepared from by following technique:
A. prescription forms: 165 parts of Radix Bupleuri, 165 parts on Pericarpium Citri Reticulatae Viride, 165 parts of Radix Scutellariaes, 165 parts of the Radix Paeoniae Albas, 66 parts of Radix Et Rhizoma Rhei, 165 parts of Radix Curcumaes, 165 parts of Herba Lysimachiaes, 165 parts of Spora Lygodii, 165 parts of Endothelium Corneum Gigeriae Galli, 165 parts of Herba Artemisiae Scopariaes, 165 parts in Rhizoma Curcumae Longae, 110 parts of rhizoma sparganic, 165 parts of Radix Clematidis;
B. preparation method: with above-mentioned 13 flavor Chinese crude drugs, in the steps below operations:
⑴ get Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Radix Scutellariae, Radix Curcumae, Rhizoma Curcumae Longae, Herba Artemisiae Scopariae, rhizoma sparganic medical material, and adding with the medical material weight ratio is that 10 times of amounts, concentration are 70% ethanol, heating extraction 2 times, and each 1.5 hours, filter, filtrate, medicinal residues are continued to employ;
⑵ mix the medicinal residues among the above-mentioned ⑴ with the Radix Paeoniae Alba, Radix Et Rhizoma Rhei, Herba Lysimachiae, Spora Lygodii, Endothelium Corneum Gigeriae Galli, clematis chinensis medicinal materials, adding with the medical material weight ratio is that 8 times of amounts, pH value are 4.0 water, heating extraction 2 times, each 1.5 hours, filter, add ethanol in the filtrate so that contain the alcohol amount and reach 70%, leave standstill, filter, filtrate is continued to employ;
⑶ mix the filtrate of continuing to employ at two places among above-mentioned ⑴ and the ⑵, and Recycled ethanol adds water to without behind the alcohol flavor, leaves standstill, and after the filtration, adds antiseptic and correctives commonly used, adds water to full dose and make oral liquid.
3. preparation method for the treatment of the Chinese medicine preparation of cholelithiasis, cholecystitis is characterized in that:
A. prescription forms: 165 parts of Radix Bupleuri, 165 parts on Pericarpium Citri Reticulatae Viride, 165 parts of Radix Scutellariaes, 165 parts of the Radix Paeoniae Albas, 66 parts of Radix Et Rhizoma Rhei, 165 parts of Radix Curcumaes, 165 parts of Herba Lysimachiaes, 165 parts of Spora Lygodii, 165 parts of Endothelium Corneum Gigeriae Galli, 165 parts of Herba Artemisiae Scopariaes, 165 parts in Rhizoma Curcumae Longae, 110 parts of rhizoma sparganic, 165 parts of Radix Clematidis;
B. preparation method: with above-mentioned 13 flavor Chinese crude drugs, in the steps below operations:
⑴ get Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Radix Scutellariae, Radix Curcumae, Rhizoma Curcumae Longae, Herba Artemisiae Scopariae, rhizoma sparganic medical material, and adding with the medical material weight ratio is that 6~12 times of amounts, concentration are 50%~80% ethanol, heating extraction 1~3 time, and each 1~2 hour, filter, filtrate, medicinal residues are continued to employ;
⑵ mix the medicinal residues among the above-mentioned ⑴ with the Radix Paeoniae Alba, Radix Et Rhizoma Rhei, Herba Lysimachiae, Spora Lygodii, Endothelium Corneum Gigeriae Galli, clematis chinensis medicinal materials, adding with the medical material weight ratio is that 5~10 times of amounts, pH value are 3.0~5.5 water, heating extraction 1~3 time, each 1~2 hour, filter, add ethanol in the filtrate so that contain the alcohol amount and reach 50%~80%, leave standstill, filter, filtrate is continued to employ;
⑶ mix the filtrate of continuing to employ at two places among above-mentioned ⑴ and the ⑵, and Recycled ethanol adds water to without behind the alcohol flavor, leaves standstill, and after the filtration, adds antiseptic and correctives commonly used, adds water to full dose and make oral liquid.
4. the preparation method of the Chinese medicine preparation for the treatment of cholelithiasis as claimed in claim 3, cholecystitis is characterized in that:
⑴ get Radix Bupleuri, Pericarpium Citri Reticulatae Viride, Radix Scutellariae, Radix Curcumae, Rhizoma Curcumae Longae, Herba Artemisiae Scopariae, rhizoma sparganic medical material, and adding with the medical material weight ratio is that 10 times of amounts, concentration are 70% ethanol, heating extraction 2 times, and each 1.5 hours, filter, filtrate, medicinal residues are continued to employ;
⑵ mix the medicinal residues among the above-mentioned ⑴ with the Radix Paeoniae Alba, Radix Et Rhizoma Rhei, Herba Lysimachiae, Spora Lygodii, Endothelium Corneum Gigeriae Galli, clematis chinensis medicinal materials, adding with the medical material weight ratio is that 8 times of amounts, pH value are 4.0 water, heating extraction 2 times, each 1.5 hours, filter, add ethanol in the filtrate so that contain the alcohol amount and reach 70%, leave standstill, filter, filtrate is continued to employ;
⑶ mix the filtrate of continuing to employ at two places among above-mentioned ⑴ and the ⑵, and Recycled ethanol adds water to without behind the alcohol flavor, leaves standstill, and after the filtration, adds antiseptic and correctives commonly used, adds water to full dose and make oral liquid.
CN2012104385589A 2012-11-06 2012-11-06 Traditional Chinese medicine preparation for treatment of gallstones and cholecystitis and preparation method thereof Pending CN102973884A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN2012104385589A CN102973884A (en) 2012-11-06 2012-11-06 Traditional Chinese medicine preparation for treatment of gallstones and cholecystitis and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2012104385589A CN102973884A (en) 2012-11-06 2012-11-06 Traditional Chinese medicine preparation for treatment of gallstones and cholecystitis and preparation method thereof

Publications (1)

Publication Number Publication Date
CN102973884A true CN102973884A (en) 2013-03-20

Family

ID=47848419

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2012104385589A Pending CN102973884A (en) 2012-11-06 2012-11-06 Traditional Chinese medicine preparation for treatment of gallstones and cholecystitis and preparation method thereof

Country Status (1)

Country Link
CN (1) CN102973884A (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1418682A (en) * 2002-11-29 2003-05-21 张慧芳 Medicine compositions for treating biliary calculus, and its prepn. method
CN1562178A (en) * 2004-03-17 2005-01-12 北京奇源益德药物研究所 Preparation of Chinese traditional medicine for curing gallstone and preparation method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1418682A (en) * 2002-11-29 2003-05-21 张慧芳 Medicine compositions for treating biliary calculus, and its prepn. method
CN1562178A (en) * 2004-03-17 2005-01-12 北京奇源益德药物研究所 Preparation of Chinese traditional medicine for curing gallstone and preparation method

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
张玲等: "不同醇沉浓度对柴胡中柴胡皂甙含量的影响", 《中草药》, vol. 26, no. 8, 31 August 1995 (1995-08-31) *
李东芬等: "芍药苷油水分配系数的测定及pH对其的影响", 《中药与临床》, vol. 2, no. 4, 31 August 2011 (2011-08-31), pages 21 - 23 *
钟晓明等: "柴胡、郁金醇提工艺研究", 《中成药》, vol. 32, no. 7, 31 July 2010 (2010-07-31), pages 1236 - 1238 *
马容等: "大黄中游离蒽醌的提取工艺优化研究", 《中草药》, vol. 39, no. 6, 30 June 2008 (2008-06-30), pages 858 - 860 *

Similar Documents

Publication Publication Date Title
CN102357197B (en) Traditional Chinese medicine composition for treating constipation
CN104524106A (en) Traditional Chinese medicine preparation for treating prostatitis and prostatic hyperplasia and preparation method thereof
CN103705796A (en) Medicinal composition for treating diarrhea, and preparation method thereof
CN103285173B (en) A kind of Chinese medicine treating thrombocytopenic purpura
CN101152532B (en) Traditional Chinese medicine preparations for treating gynecology disease
CN103191399A (en) Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period
CN100389796C (en) Chinese medicinal preparation for treating chronic prostatitis and its manufacturing method
CN103169863B (en) Medicament for treating constipation and preparation method thereof
CN102961680B (en) Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof
CN104840864B (en) A kind of Chinese medicine preparation for the treatment of infantile spleen deficiency type diarrhoea
CN102961677B (en) Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof
CN102961678B (en) Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof
CN102973884A (en) Traditional Chinese medicine preparation for treatment of gallstones and cholecystitis and preparation method thereof
CN104491316B (en) A kind of Chinese medicine preparation for the treatment of deficiency of QI in middle-JIAO type hyperplasia of prostate
CN102961676B (en) Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof
CN102961679B (en) Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof
CN103251751B (en) Traditional Chinese medicine composition for treating primary dysmenorrheal and preparation method thereof
CN101862376B (en) Medicament for treating oviduct obstructive infertility and preparation method thereof
CN102940674B (en) Medicine composition for treating benign prostatic hyperplasia
CN101879227B (en) Chinese medicinal composition for treating protrusion of lumbar intervertebral disci and preparation method thereof
CN102973883A (en) Traditional Chinese medicine preparation for treatment of gallstones and cholecystitis and preparation method thereof
CN105288315A (en) Christina loosestrife herb oral liquid for clearing away heat, removing dampness, benefiting bile and expelling toxin and preparation method of christina loosestrife herb oral liquid
CN105920436A (en) Medicinal preparation for treating lung cancer and preparation method thereof
CN104491312A (en) Use of tradtional Chinese medicine preparation in preparing medicines for treating prostatitis and prostatauxe
CN105381273A (en) Medicine composition for treating diabetes and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130320